spacer
home > ict > autumn 2017 > revolutionary potential
PUBLICATIONS
International Clinical Trials

Revolutionary Potential

For clinical research, the shift away from paper has been a
long and gradual process. Decades have now passed since
electronic data capture (EDC) was first implemented in a trial,
yet, to this day, some researchers remain beholden to paper
case report forms (CRFs) and databases. In fact, even those
who have switched are not fully electronic, as data is only
entered into the system after it is captured on a paper CRF at
the site level. In other words, while EDC has taken great strides
in modernising the operations of clinical data managers,
workflows at the site level are largely the same – as far as
data capture is concerned – as before the emergence of
eClinical technology.

This is one of the central reasons why the advent of eSource
technology – which allows data to be entered directly into
an electronic system and shared remotely with no paper
involved – represents a watershed moment for research.
eSource is largely seen as an improvement to timelines and
data integrity and, therefore, a boon for sponsors and CROs.
However, it is from these sites that these improvements
emanate.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mike Novotny is founder and CEO at Medrio. He previously served as President of the EDC software company Ninaza before founding Medrio in 2005. Mike has 20 years of experience in research and software and holds a BA from Stanford University, US, and an MBA from Columbia University, US.

Nick O’Brien
is Marketing Copywriter at Medrio, where he writes the company blog as well as press releases and other copy. He has extensive experience writing for blogs and other media and holds a BA in English, with an emphasis on creative writing, from Kenyon College, US.
spacer
Mike Novotny
spacer
spacer
spacer
Nick O'Brien
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Synpromics expands facilities to meet demand for revolutionary gene control technology

Edinburgh, UK, 11th September 2017 - Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the Roslin Innovation Centre. Synpromics is expanding to meet increasing global demand for its cutting-edge gene control technology, and is the first company to move into the new custom-built centre based at the University of Edinburgh’s Easter Bush Campus.
More info >>

White Papers

Successfully managing the unique demands of cell therapy supply chains

PCI Pharma Services

Cell therapy professionals joined a specialist webinar by industry experts from PCI Clinical Services and TrakCel, addressing the unique complexity of an autologous therapy supply chain. Hosted by European Pharmaceutical Manufacturer magazine, the webinar was delivered by Rachel Griffiths, Associate Director, Technical Services, PCI Clinincal Services, and Dr. Matthew Lakelin, Vice President, Scientific Affairs and Business Development, TrakCel . Here, we present the white paper from that webinar event.
More info >>

 
Industry Events

11th Annual Proteins & Antibodies Congress

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our esteemed 11thAnnual Proteins & Antibodies Congress 2018, 16th – 17th April 2018, London, UK. Over 450 proteins, antibodies, peptides and biosimilars & biobetters attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement